Literature DB >> 26366797

Treatment of the genitourinary syndrome of menopause.

S Palacios1, A Mejía1, J L Neyro2.   

Abstract

The vagina, vulva, vestibule, labia majora/minora, and bladder trigone have a high concentration of estrogen receptors; therefore, they are a sensitive biological indicator of serum levels of these hormones in women. The estrogen loss in postmenopausal women produces a dysfunction called genitourinary syndrome of menopause. The principal therapeutic goal in the genitourinary syndrome of menopause is to relieve symptoms. Treatment options, as well as local and systemic hormonal treatment are changes in lifestyle and non-hormonal treatments mainly based on the use of moisturizers and lubricants. New treatments that have recently appeared are ospemifeme, the first selective hormone receptor modulator for dyspareunia and vulvovaginal atrophy treatment, and the use of vaginal laser. This review has been written with the intention of giving recommendations on the prevention and treatment of genitourinary syndrome of menopause.

Entities:  

Keywords:  GENITOURINARY SYNDROME OF MENOPAUSE; MOISTURIZERS; OSPEMIFENE; SYSTEMIC AND LOCAL ESTROGEN; TSEC; VAGINAL LASER

Mesh:

Substances:

Year:  2015        PMID: 26366797     DOI: 10.3109/13697137.2015.1079100

Source DB:  PubMed          Journal:  Climacteric        ISSN: 1369-7137            Impact factor:   3.005


  13 in total

Review 1.  Laser therapy as a treatment modality for genitourinary syndrome of menopause: a critical appraisal of evidence.

Authors:  Angamuthu Arunkalaivanan; Hervinder Kaur; Oseka Onuma
Journal:  Int Urogynecol J       Date:  2017-02-02       Impact factor: 2.894

Review 2.  A clinical guide to the management of genitourinary symptoms in breast cancer survivors on endocrine therapy.

Authors:  Mariana S Sousa; Michelle Peate; Sherin Jarvis; Martha Hickey; Michael Friedlander
Journal:  Ther Adv Med Oncol       Date:  2017-01-31       Impact factor: 8.168

3.  Ablative dual-phase Erbium:YAG laser treatment of atrophy-related vaginal symptoms in post-menopausal breast cancer survivors omitting hormonal treatment.

Authors:  A R Mothes; M Runnebaum; I B Runnebaum
Journal:  J Cancer Res Clin Oncol       Date:  2018-02-27       Impact factor: 4.553

4.  Anti-Müllerian hormone and its relationships with subclinical cardiovascular disease and renal disease in a longitudinal cohort study of women with type 1 diabetes.

Authors:  Catherine Kim; Yuanyuan Pan; Barbara H Braffett; Valerie L Arends; Michael W Steffes; Hunter Wessells; Aruna V Sarma
Journal:  Womens Midlife Health       Date:  2017-08-18

Review 5.  Modern management of genitourinary syndrome of menopause.

Authors:  Ana Sofia Da Silva; Georgina Baines; George Araklitis; Dudley Robinson; Linda Cardozo
Journal:  Fac Rev       Date:  2021-03-03

Review 6.  Management of genitourinary syndrome of menopause in breast cancer survivors: An update.

Authors:  Daniel María Lubián López
Journal:  World J Clin Oncol       Date:  2022-02-24

Review 7.  Diagnosis and management of symptoms associated with vulvovaginal atrophy: expert opinion on behalf of the Italian VVA study group.

Authors:  Rossella E Nappi; Nicoletta Biglia; Angelo Cagnacci; Costantino Di Carlo; Stefano Luisi; Anna Maria Paoletti
Journal:  Gynecol Endocrinol       Date:  2016-05-17       Impact factor: 2.260

Review 8.  The Genitourinary Syndrome of Menopause: An Overview of the Recent Data.

Authors:  Kyveli Angelou; Themos Grigoriadis; Michail Diakosavvas; Dimitris Zacharakis; Stavros Athanasiou
Journal:  Cureus       Date:  2020-04-08

Review 9.  Signs and symptoms, evaluation, and management of genitourinary tract consequences of premature ovarian insufficiency.

Authors:  Anna Calik-Ksepka; Monika Grymowicz; Ewa Rudnicka; Jolanta Skórska; Paulina Machura; Wojciech Pięta; Roman Smolarczyk
Journal:  Prz Menopauzalny       Date:  2018-09-30

Review 10.  Postmenopausal women in gynecological care.

Authors:  Magdalena Pertyńska-Marczewska; Tomasz Pertyński
Journal:  Prz Menopauzalny       Date:  2021-06-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.